Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06574958
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
None
First Post:
2024-08-13
Brief Title:
Clinical Study of CD38CS1 Chimeric Antigen Receptor T Cells in the Treatment of RefractoryRecurrent Multiple Myeloma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Professor of Medicine Second Hospital of Shandong University
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators developed a dual-target CAR-T targeting CD38 and CS1 Previous experimental results showed that the investigators double-target CAR-T not only had a good killing effect on CD38CS1 double-positive tumor cells but also had a high killing rate on CD38 or CS1 single-positive tumor cells The investigators further study also found that the killing rate of the investigators dual-target CAR-T after mixing CD38 and CS1 monoyang tumor cells was over 80 The advantage of the investigators dual-target CAR-T product is that the killing effect on single-yang double-yang and single-yang mixed tumors is stable and the killing rate is above 80 see Figure 1 It has a wide killing range and can effectively reduce the phenomenon of tumor immune escape Therefore the investigators dual CAR products have good advantages and development potential
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None